Novo Nordisk's Wegovy Pill to Hit US Shelves in January 2026 After Winning Approval

01:11 AM EST, 12/23/2025 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) is poised to roll out its once-daily Wegovy pill in the US in early January 2026, after the Food and Drug Administration approved it as the first oral glucagon-like peptide-1 receptor agonist therapy for weight management. The Danish drugmaker's 25-milligram daily oral dose of semaglutide is indicated to reduce body weight and lower the risk of adverse cardiovascular events, according to a Monday release. Injectable Wegovy, a once-weekly 2.4-mg semaglutide shot, has been approved in the US since 2021. "With today's approval of the Wegovy pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," said Chief Executive Officer Mike Doustdar. "No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy pill, and we are very excited for what this will mean for patients in the US." The latest approval is backed by the Oasis 4 and Select trials, during which the pill demonstrated a mean weight loss of 16.6% in adults who took the pill once daily and were obese or overweight with at least one weight-related comorbid condition. Furthermore, one in three patients in Oasis 4 achieved weight loss of 20% or more, comparable to injectable Wegovy, with a similar safety and tolerability profile. Indicated to maintain weight loss in the long term, oral Wegovy is pending marketing consent from the European Medicines Agency and other regulatory authorities, which have greenlit the injectable version of the drug.